Taysha Gene Therapies, Inc. (TSHA): who owns it and who trades it
As of Nov 16, 2026, TSHA insiders reported 12 open-market sales worth $6.7M and no purchases in the last 12 months, with 46% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sukumar Nagendran (President), with $5.3M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Taysha Gene Therapies
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TSHA
208 funds and institutions reported TSHA shares worth $2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Avoro Capital Advisors LLC with 8.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 23.89M | 8.32% | $163M | +10% |
| Ra Capital Management, L.P. | 23.56M | 8.20% | $160M | No change |
| Goldman Sachs Group Inc | 22.71M | 7.91% | $155M | +2% |
| BlackRock, Inc. | 20.69M | 7.20% | $141M | +13% |
| Vestal Point Capital, LP | 19.41M | 6.76% | $132M | +8% |
| Morgan Stanley | 16.49M | 5.74% | $112M | -8% |
| Rtw Investments, LP | 13.56M | 4.72% | $92.3M | -1% |
| FMR LLC (Fidelity) | 13.34M | 4.64% | $90.8M | -7% |
| Vanguard Capital Management LLC | 12.48M | 4.34% | $85M | +22% |
| State Street Corp | 11.42M | 3.98% | $77.8M | +2% |
| Siren, L.L.C. | 9.85M | 3.43% | $67.1M | +12% |
| Octagon Capital Advisors LP | 9.69M | 3.37% | $66M | +9% |
| Geode Capital Management, LLC | 6.56M | 2.28% | $44.7M | +19% |
| Polar Capital Holdings Plc | 5.12M | 1.78% | $34.8M | -10% |
| Mpm Bioimpact LLC | 4.50M | 1.57% | $30.6M | – |
| D. E. Shaw & Co., Inc. | 4.40M | 1.53% | $30M | -1% |
| Baker Bros. Advisors LP | 4.00M | 1.39% | $27.3M | No change |
| Wellington Management Group LLP | 3.98M | 1.38% | $27.1M | +535% |
| Healthcare of Ontario Pension Plan Trust Fund | 3.89M | 1.35% | $26.5M | +35% |
| Casdin Capital, LLC | 3.25M | 1.13% | $22.1M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TSHA insiders reported $0 of open-market purchases and $6.7M of sales. 46% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | Sukumar Nagendran | President | Sale plan | 200,000 | $6.24 | $1.2M | Form 4 |
| Apr 10, 2026 | Sukumar Nagendran | President | Sale plan | 200,000 | $4.46 | $892K | Form 4 |
| Feb 4, 2026 | Kamran Alam | CFO | Sale | 1,655 | $4.52 | $7.5K | Form 4 |
| Jan 26, 2026 | Sukumar Nagendran | President | Sale | 26,918 | $4.61 | $124K | Form 4 |
| Jan 26, 2026 | Sean P. Nolan | CEO | Sale | 41,312 | $4.61 | $190K | Form 4 |
| Jan 26, 2026 | Kamran Alam | CFO | Sale | 23,849 | $4.61 | $110K | Form 4 |
| Jan 23, 2026 | Sukumar Nagendran | President | Sale | 89,132 | $4.75 | $423K | Form 4 |
| Jan 23, 2026 | Sean P. Nolan | CEO | Sale | 136,789 | $4.75 | $650K | Form 4 |
| Jan 23, 2026 | Kamran Alam | CFO | Sale | 78,968 | $4.75 | $375K | Form 4 |
| Jan 12, 2026 | Sukumar Nagendran | President | Sale plan | 200,000 | $4.71 | $942K | Form 4 |
| Dec 1, 2025 | Sukumar Nagendran | President | Sale | 260,047 | $4.51 | $1.2M | Form 4 |
| Nov 28, 2025 | Sukumar Nagendran | President | Sale | 110,125 | $4.75 | $523K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Sukumar Nagendran | President and Head of R&D, Director | – | $5.3M | Jul 10, 2026 |
| Sean P. Nolan | Chief Executive Officer, Director | – | $840K | Jan 26, 2026 |
| Kamran Alam | CHIEF FINANCIAL OFFICER | – | $493K | Feb 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TSHA short interest
High short interest. 16.4% of TSHA shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 46%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 53.48M TSHA shares were sold short, 16.4% of the shares outstanding, up 4.3% from the report before. At the average daily volume of 3.62M shares, buying them all back would take about 14.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 53.48M | 16.41% | +4% | 3.62M | 14.8 |
| Oct 15, 2026 | 51.25M | 15.73% | -7% | 4.43M | 11.6 |
| Sep 30, 2026 | 55.02M | 16.89% | +7% | 4.93M | 11.2 |
| Sep 15, 2026 | 51.41M | 15.78% | +10% | 2.74M | 18.8 |
| Aug 31, 2026 | 46.80M | 14.36% | +0% | 2.41M | 19.4 |
| Aug 14, 2026 | 46.74M | 14.34% | +0% | 2.68M | 17.4 |
| Jul 31, 2026 | 46.69M | 16.25% | +3% | 2.46M | 19.0 |
| Jul 15, 2026 | 45.29M | 15.77% | +9% | 3.39M | 13.3 |
| Jun 30, 2026 | 41.40M | 14.41% | +7% | 5.14M | 8.1 |
| Jun 15, 2026 | 38.73M | 13.48% | +8% | 2.52M | 15.4 |
| May 29, 2026 | 36.01M | 12.54% | -2% | 2.20M | 16.4 |
| May 15, 2026 | 36.70M | 12.78% | -8% | 2.43M | 15.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Taysha Gene Therapies company events
Taysha Gene Therapies filed 6 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 11, 2026.
- Aug 11, 2026ResultsReleased financial results. Filing
- Jun 25, 2026AgreementTaysha Gene Therapies, Inc. entered into an underwriting agreement with Jefferies LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters set forth therein, to issue and sell 32,500,001 shares of common stock of the Company, par value $0.00001 per share, and, in lieu of… Filing
- Jun 22, 2026AnnouncementThe Company also made available a presentation to be used to discuss the clinical and regulatory updates on TSHA-102. Filing
- Jun 2, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Mar 19, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Taysha Gene Therapies financials
Famous investors that hold TSHA
3 of the 50 well-known investors we track reported holding TSHA in their latest 13F filing. The largest position is Ken Griffin's, worth $16M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 3.29M | $16M | 0.0% | +114% |
| Israel Englander · Millennium Management | Q3 2026 | 2.00M | $9.7M | 0.0% | -6% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 130,473 | $635K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TSHA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 9.9% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 9.9% |
Questions about Taysha Gene Therapies, Inc. (TSHA) stock
Who owns the most TSHA stock?
The largest reported owner of Taysha Gene Therapies, Inc. (TSHA) is Avoro Capital Advisors LLC, with 8.3% of the company. In total, 208 funds and institutions reported holding TSHA at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are TSHA insiders buying or selling?
In the last 12 months, TSHA insiders reported no open-market purchases and 12 sales worth $6.7M. The latest trade was on Jul 10, 2026. See every trade.
What is the short interest in TSHA?
As of Oct 30, 2026, 53.48M TSHA shares were sold short, 16.4% of the shares outstanding, up 4.3% from the report before. At the average daily volume of 3.62M shares, buying them all back would take about 14.8 trading days (days to cover). See the history.
Which famous investors hold TSHA?
3 of the 50 well-known investors we track reported TSHA in their latest 13F filing, including Ken Griffin, Israel Englander, Paul Tudor Jones. The largest position is worth $16M. See all holders.
Executive pay
Taysha Gene Therapies's chief executive was paid a total of $4.1M for the year ended Dec 31, 2025, down 13% from $4.7M the year before. In the last 12 months, Taysha Gene Therapies's executives and directors bought no stock on the open market and sold $6.7M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.